Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.

ClinicalTrials.gov ID: NCT01750281

Public ClinicalTrials.gov record NCT01750281. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will also help us to understand the tolerability profile of the different dosing regimens in these patients

Study identification

NCT ID: NCT01750281
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 212 participants

Conditions and interventions

Conditions

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 17, 2012
Primary completion: Jan 26, 2016
Completion: Oct 30, 2022
Last update posted: Oct 23, 2023

2012 – 2022

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Santa Monica	California	90404	—
Research Site	Aurora	Colorado	80045	—
Research Site	Hollywood	Florida	33028	—
Research Site	Atlanta	Georgia	30318	—
Research Site	Chicago	Illinois	60637	—
Research Site	Marrero	Louisiana	70072	—
Research Site	Boston	Massachusetts	02215	—
Research Site	Mineola	New York	11501	—
Research Site	New York	New York	10011	—
Research Site	New York	New York	10032	—
Research Site	Hershey	Pennsylvania	17033-0850	—
Research Site	Philadelphia	Pennsylvania	19107	—
Research Site	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 55 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01750281, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 23, 2023 · Synced Sep 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01750281 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →